YOLFTbeta
Revelation Biosciences Inc

Revelation Biosciences Inc

REVB · NASDAQ · Healthcare / Biotechnology

4.27USD-0.12 (-2.63%)

Price History

Full chart

Market Stats

Previous Close4.38
Open4.38
Day Range4.17 – 4.50
52-Week Range0.83 – 6.76
Volume6.55K
Market Cap3.47M
P/E (TTM)0.03
Forward P/E0.89
EPS27.03
Dividend Yield0.00%
Beta-0.14
50-Day Avg1.04
200-Day Avg1.54

About

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. James M. Rolke
  • Employees8
  • Headquarters4660 La Jolla Village Drive, San Diego, CA, United States, 92122, USA
  • Websitehttps://www.revbiosciences.com

Leadership

  • Mr. James M. RolkeChairman & CEO · b. 1969
  • Mr. Chester Stanley Zygmont IIICFO & Corporate Secretary · b. 1980
  • Ms. Sandra VedrickVice President of Human Resources & Investor Relations
  • Ms. Carol OdleSenior Director of Clinical Projects

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue21.07M27.66M48.81M74.00M85.11M95.81M-00000
Growth (%)-+31.26%+76.46%+51.60%+15.02%+12.57%------
Cost of Revenue00000--69.17K40.01K25.05K27.92K27.06K
Gross Profit21.07M27.66M45.25M70.82M80.98M90.91M--69.17K-40.01K-25.05K-27.92K-27.06K
Gross Margin100.00%100.00%92.69%95.71%95.15%94.88%------
Operating Expense13.63M17.39M26.49M38.14M42.09M90.91M-11.88M10.82M8.63M7.95M9.04M
Operating Income7.45M10.28M18.76M32.69M38.89M-3.64K-145.49K-11.95M-10.86M-8.66M-7.98M-9.07M
Operating Margin35.33%37.15%38.43%44.17%45.70%-0.00%------
EBITDA------3.64K-145.49K-11.93M-10.84M-8.63M-7.95M-9.04M
EBITDA Margin------0.00%------
Net Income4.50M6.20M8.78M16.27M27.63M-3.64K-136.41K-11.99M-10.83M-120.25K-15.04M-8.91M
Net Income Margin21.38%22.42%17.98%21.99%32.46%-0.00%------
R&D------2.56K6.91M5.38M4.15M3.55M4.06M
Interest Expense000000041.76K34.96K---
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%------

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.89B2.10B2.46B22.67K74.16M2.04M5.50M12.21M6.62M11.58M
Total Liabilities1.73B1.91B2.19B26.31K6.34M2.14M4.45M5.56M1.91M2.72M
Total Equity168.76M188.28M264.89M-3.64K67.82M-99.47K1.05M6.65M4.71M8.86M
Cash111.53M72.20M136.44M147.12M11.73K1.27M5.25M11.99M6.50M10.70M
Total Debt-----16.75K---746.78K
Net Debt-----11.73K-1.26M-5.25M-11.99M-6.50M-9.95M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.60M11.60M24.25M32.58M41.09M-215.07K-11.09M-11.22M-7.29M-18.32M-8.27M
Investing Cash Flow--196.67M-196.67M-251.59M-294.85M--74.04M-131.96K---19.17K-
Financing Cash Flow-270.02M270.02M186.71M327.97M338.19M74.26M8.00M15.20M14.03M12.85M12.47M
Capital Expenditure0582.00K582.00K804.00K861.00K526.00K4131.96K4419.17K0
Free Cash Flow-------215.07K-11.22M-11.22M-7.29M-18.34M-8.27M
Dividends Paid--------7.65M--5.95B
FCF to OCF------100.00%101.19%100.00%100.00%100.10%100.00%
Dividend Paid to FCF---------68.21%---71968.92%

Earnings

Report DateNov 9, 2018Jan 29, 2019Apr 29, 2019Jul 24, 2019Oct 24, 2019Jan 28, 2020Nov 16, 2020Dec 31, 2020Jun 22, 2021Aug 23, 2021Oct 29, 2021Dec 31, 2021May 16, 2022Aug 15, 2022Nov 10, 2022Mar 30, 2023May 22, 2023Aug 11, 2023Nov 9, 2023Mar 22, 2024May 10, 2024Aug 9, 2024Nov 8, 2024Mar 20, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.650.610.610.640.68-0.00------28224.06-28224.06-18144.04-10080.01-0.65-1872.00-1929.60-13.77-1033.92-346.56-545.28-10.32-82.56-4.46-5.34-1.41-1.15-0.83-0.88
EPS Actual0.650.590.620.650.690.650.00-35941.58-0.16-0.73-0.42-29509.83-94752.20-24192.05-12096.03-12904.142.79-1854.72-2488.78-8.33-472.32-984.96-161.28-4.98-25.32-7.01-7.08-1.65-2.71-0.87-
Surprise0.00%-3.28%1.64%1.56%1.47%--------235.71%14.29%33.33%-28.02%529.23%0.92%-28.98%39.51%54.32%-184.21%70.42%51.74%69.33%-57.17%-32.58%-17.02%-135.65%-4.82%-
TimingPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursPre-marketAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-After-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.47M
Enterprise Value-6.84M
Trailing P/E0.03
Forward P/E0.89
Price / Sales2.88
Price / Book0.39
EPS27.03
Book Value2.58
Revenue (TTM)0
Gross Profit (TTM)90.91M
EBITDA-11.24M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-154.77%
Return on Assets-78.73%
Shares Outstanding3.98M
Shares Float3.05M
Beta-0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 17.75
  • Buy
    1

Ownership Breakdown

Institutions
12.89%
Insiders
12.34%
Retail / Other
74.77%

Top Institutional Holders

  • Armistice Capital, LLC
    323.24K8.11%
  • Sabby Management LLC
    99.43K2.50%
  • Geode Capital Management, LLC
    43.20K1.08%
  • Citadel Advisors Llc
    38.58K0.97%
  • Vanguard Fiduciary Trust Co
    13.13K0.33%
  • XTX Topco Ltd
    11.38K0.29%
  • UBS Group AG
    4.12K0.10%
  • Tower Research Capital LLC
    4.07K0.10%
  • Royal Bank of Canada
    7470.02%
  • SBI Securities Co Ltd
    3440.01%
  • BNP Paribas Investment Partners SA
    90.00%
  • Caitong International Asset Management Co., Limited.
    00.00%
  • Northern Trust Corp
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    16.64K0.42%

Stock Splits

  • Oct 20, 20261:7
  • Jan 28, 20261:4
  • Jul 7, 20251:3
  • Jan 28, 20251:16
  • Jan 25, 20241:30
  • Feb 1, 20231:35